title: NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated             by gonadotrophin and sex-steroid hormones.
abstract: Aberrant nuclear factor-erythroid 2 (NRF2) expression correlates with tumor             development. We investigated NRF2 expression in ovarian epithelial carcinoma (OEC),             aiming to identify associations with clinicopathological factors, hormones and             induced reactive oxygen species (ROS). Immunohistochemical staining for NRF2 expression             was performed on 10 benign cystadenomas, 4 boderline tumors and 64 OECs. Western             blotting was used to determine the effects of hormones on NRF2 expression in OEC.             NRF2 protein was found to be overexpressed in OEC. Gonadotrophins and estrogen             induced ROS production in OEC; these hormones also enhanced NRF2 expression. Therefore,             aberrant expression may be induced by hormones through ROS signaling. Increased             NRF2 expression may be a molecular event in OEC carcinogenesis.
authors.affiliation: Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, PR China.
authors.forename: Hong
authors.initials: H
authors.lastname: Liao
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhou
authors.forename: Zhenbo
authors.initials: Z
authors.lastname: Zhang
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Wang
authors.forename: Yunyan
authors.initials: Y
authors.lastname: Sun
authors.forename: Xiaofang
authors.initials: X
authors.lastname: Yi
authors.forename: Youji
authors.initials: Y
authors.lastname: Feng
mesh_terms: D000328:Adult; D000368:Aged; D000077216:Carcinoma, Ovarian Epithelial; D045744:Cell Line, Tumor; D003537:Cystadenoma / Q000378:metabolism; D004958:Estradiol / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism / Q000494:pharmacology; D012739:Gonadal Steroid Hormones / Q000378:metabolism* / Q000494:pharmacology; D006062:Gonadotropins / Q000378:metabolism*; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism / Q000494:pharmacology; D008525:Medroxyprogesterone / Q000378:metabolism / Q000494:pharmacology; D008875:Middle Aged; D051267:NF-E2-Related Factor 2 / Q000096:biosynthesis*; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D018384:Oxidative Stress; D017382:Reactive Oxygen Species / Q000378:metabolism; D015398:Signal Transduction; D055815:Young Adult
chemical_list: D012739:Gonadal Steroid Hormones; D006062:Gonadotropins; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; D017382:Reactive Oxygen Species; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008525:Medroxyprogesterone